• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyndra lands $105m deal with Allergan for once-weekly Alzheimer’s drugs

September 8, 2017 By Sarah Faulkner

LyndraBoston-based startup Lyndra said today that it is partnering with pharma giant Allergan (NYSE:AGN) to develop orally administered, once-weekly products for the treatment of Alzheimer’s disease.

The collaboration will combine Allergan’s proprietary Alzheimer’s drugs with Lyndra’s sustained-release technology, which is designed to temporarily reside in the stomach for up to one week while delivering a drug.

According to the deal, Allergan is slated to pay $15 million upfront to Lyndra, with the potential for an additional $90 million in development and regulatory milestones. The deal also leaves room for Allergan to select an additional compound, from any therapeutic category, for inclusion in the collaboration.

The partnership with Allergan is Lyndra’s largest deal to date.

“I am delighted that we have the opportunity to work so closely with the scientific team at Allergan to bring caregiver and patient innovation to this critical illness,” Lyndra CEO Amy Schulman said in prepared remarks. “The chance to minimize the struggle with the daily pill can make a real difference to patients and their caregivers, ease the burden of medication compliance and simplify the day-to-day challenges of chronic conditions. As a team, we at Lyndra are deeply committed to making a difference in how people get well and our ultra-long-acting sustained release technology is built on the premise that a once-weekly oral pill will make a real difference in disease treatment and prevention.”

“As a leader in Alzheimer’s treatment, Allergan is committed to developing new approaches that further reduce the burden of treatment for patients and their caregivers,” Allergan’s SVP of pharmaceutical development, Sesha Neervanan, added. “In addition to its potential application in Alzheimer’s disease treatment, we are excited by the potential for these technologies that could unlock a paradigm shift in the treatment of other conditions where less frequent administration is critical to improving compliance and patient care.”

Lyndra’s technology, developed by Robert Langer at the Massachusetts Institute of Technology, is a star-shaped pill loaded with drugs that remains in the gastric cavity after it been swallowed. After the drugs have been released, the pill splits into small pieces and safely passes through the GI tract, according to Lyndra.

“The astounding reality is that while there are so many effective, life-saving treatments available, nearly 50% of patients don’t adhere to their medication regimens which leads to avoidable negative health outcomes and pre-mature deaths,” Langer said. “We are delighted that Allergan shares in our vision of developing novel, long-acting technologies that transform how patients take medicine and take full advantage of available treatments.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, lyndra

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS